



9 April 2003



03050367

Securities and Exchange Commission
Judiciary Plaza,
450 Fifth Street,
Washington DC 20549



SUPPL

Re: Bionomics Limited - File number 82-34682

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.

Yours sincerely

A handwritten signature in black ink, appearing to be "Jill Mashado".

Jill Mashado
Company Secretary

PROCESSED
MAY 20 2003
THOMSON
FINANCIAL

dlw 5/13

ABN AMRO Morgans Healthcare and Biotech Forum

10 April 2003

April

Bionomics



Bionomics Mission

- Exploit our proprietary genomics-driven discovery platforms to discover and develop innovative medical products.
- Focus on diseases in need of new medical treatments with large commercial markets:
 - CNS disorders
 - Cancer

April 2003

Financials

Cash position at 31 December 2002 \$6.7 mill

Net cash burn (1 July – 31 December 2002) \$1.9 mill

Cash outflow \$2.7 mill
(compared with \$3.5 mill for 1 July – 31 December 2001)

Loss to 31 December 2002 \$2.5 mill
((\$0.3 mill attributable to depreciation))

April 2003

CNS Program – strong progress in

2002.....

- Epilepsy diagnostic product deal with Nanogen Inc.
- Proprietary position expanded
 - THE mouse - patented
 - Drug screening strategy – patented
 - Patent position on genes strengthened and progressed
- Creation of proprietary ionX™ Drug Discovery Platform

April 2003

Bionomics




.....continued into 2003


- R&D START Grant \$2.9 mill over 2 years
- Collaboration with Howard Florey – Australia's premier neuroscience institute
- Appointment of Errol De Souza to SAB

April 2003


Bionomics



ionX™ Components






Combination of NRI(N598Q/R) on switch ant



loxP

short  NEO

long arm 10 kb



April 2003

ionX™ - entry point to significant CNS opportunities

- CNS disorders are the second largest segment of the pharma market:
 - US\$52 billion in 2001
 - forecast to grow to \$75 billion by 2006

April 2003

Bionomics' Drug Discovery is targeting the GABA receptor

- Epilepsy
- Anxiety
- Insomnia
- Depression
- Bipolar Disease
- Obsessive compulsive disorder
- Migraine
- Cognitive impairment
- Cerebral ischaemia
- Schizophrenia

April 2003

Bionomics  Limited

Potential Returns From CNS Drug Discovery – 2002 deals....

- Neurosearch – Boehringer Ingelheim
 - Preclinical candidate – Alzheimer's Disease
 - Total deal value – US\$90 mill + royalties
 - Upfront payment – US\$20 mill
- Memory Pharmaceuticals – Roche
 - Preclinical candidate - Alzheimer's Disease and other CNS disorders
 - Total deal value - US\$150 million + royalties

April 2003

Sources of Cashflow

- Epilepsy diagnostic product(s)
- NeoVasc™ Mouse
- Validated targets
- ionX™ partnership
- Grant funds

April 2003

***Commercializing gene discoveries
to revolutionize medical treatments***

APB

Bionomics

